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114. PSYCHOLOGICAL ISSUES 
1. INTRODUCTION
jj CF is a chronic condition that requires a demanding and time-consuming regimen. CF 
patients are used to coping with it since childhood, but survival into adulthood and 
progressive health decline bring about new challenges. 
jj Depression, anxiety, disordered eating, compliance issues and other disturbances 
reaching a symptomatic level or not, as well as unhealthy family dynamics, deve-
lopmental and relational difficulties and existential questions may arise in adult CF 
patients. 
jj A large body of research suggests that psychological issues of CF patients
js are strongly linked to their physical condition and to an increased healthcare utilization 
and costs
js have a major impact on crucial aspects, such as adherence, BMI and lung 
function
js Therefore, psychological prevention, evaluation and possible intervention in patients, 
their families or significant others should be an integral part of CF care.
js CF teams should include a trained psychologist/psychiatrist, who works in close 
collaboration with the team members and, if needed, offers advice for the psychological 
understanding of patients (Table 1, Figure 1).
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Table 1: Role of the mental health worker in the CF center 
Systematic annual screening Clinical interview, optional questionnaires
Propose management and coping strategies to improve 
psychological health and its impact on clinical care
Organization of appropriate treatment and follow-up
Possible intervention during acute 
events
Transition from pediatric to adult care
Parenthood
Transition to transplantation
Transition to palliative care
Collaboration with the CF team Advice for the psychological understanding of patients
Provide advice that may ease negative issues with 
patients
14 Psychological issues in CF V9 MH-mc.indd   1 30/05/18   8:22 PM
2 14. PSYCHOLOGICAL ISSUES 
Table 2: Examples of the impact of CF on sensitive aspects of life 
Life event Challenges for CF patients
Reaching autonomy Transition from a pediatric to an adult setting 
and taking responsibility for treatment
Entering academic studies/education Adjusting to part-time studies 
Planning a professional future Work interrupted by hospitalizations and medi-
cal appointments 
Engaging in sentimental relationships/sexuality Coping with and sharing the limitations in inti-
macy due to the disease and its treatments
Coping with the desire of a child Facing fertility problems for males
Facing a possible health decline in case of 
pregnancy
Fear of dying before children have grown up
Facing an open  future Dealing with a shortened life expectancy, 
transplantation and palliative care
Figure 1: Key time-points of interventions of the mental health worker during the 
life span of adult CF patients
Childhood
annual screening
transition from
pediatric to
adult care parenthood
end of life
palliative care
possible transplantations
2. IMPACT OF CF ON SENSITIVE ASPECTS OF LIFE 
jj Like all young adults, at adulthood, CF patients face new challenges that are often heavily 
affected by CF. Particularly, progressive health decline (mainly loss of lung function) re-
quires more intensive and invasive treatments. Table 2 presents some examples of the 
impact of CF on sensitive aspects of life.
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jj Normalcy and stigma: Young CF patients often experience stigma (related for example 
to repetitive cough or digestive disturbance). The latter is associated with depression, 
lower QoL (quality of life) and diminished psychological health. Optimism may play a pro-
tective role. 
jj Quality of life: 
js Interestingly, QoL is more related to mental health status than to lung function, though 
QoL of CF patients decreases with health deterioration. 
js Being enrolled in professional life or studying is related to a higher QoL.
js Coping strategies also influence  QoL of CF patients
 – Active coping is positively related to social QoL; greater use of religion, spiritual co-
ping, instrumental coping and acceptance are associated with better emotional QoL.
 – Distraction coping, disengagement and substance abuse are associated with lower 
emotional QoL.
3. PSYCHOLOGICAL ISSUES IN CF PATIENTS
jj Anxiety and depression 
js Prevalence: 
 – Although somewhat debated, recent studies indicate a higher prevalence of anxiety 
and depression in CF patients compared to the general population.
js Consequences of anxiety and depression
 – In adults, anxiety and depression have been associated with lower lung function, 
increased chest symptoms, reduced physical functioning, lower BMI and increased 
frequency of hospitalizations, healthcare utilization and costs.
 – CF patients suffering from anxiety and depression report a lower QoL.
 – Psychological problems such as depression can also lead to conflicts with the CF 
team and diminished adherence to treatment, often related to doubts about medica-
tion efficacy. On the other side, good illness acceptance has been associated with 
less depressive symptoms and better adjustment to treatment.
jj Other psychological issues
js Disordered eating and eating disorders: 
 – Nutrition is a major issue for CF patients. Pressure to eat and impaired family functio-
ning during meals is often observed.
 – Although a higher prevalence of eating disorders has not been clearly established in 
CF patients compared to normal adults, CF patients are at risk of disturbed eating 
attitudes and/or behaviors. When present, they induce poor nutritional status that 
may lead to retarded or diminished growth, delayed puberty, impaired lung function 
and reduced survival.
 – Body image:  Female CF patients may have a better body image than males, given 
their preference for a low body weight, but their reduced weight can compromise their 
survival. In this regard, male CF patients may be more motivated to follow nutritional 
recommendations. Greater dissatisfaction with body image, poorer self-esteem and 
lower QoL has been reported in adults with enteral-tube feeding.
14 Psychological issues in CF V9 MH-mc.indd   3 30/05/18   8:22 PM
4 14. PSYCHOLOGICAL ISSUES 
js Psychological distress can be encountered without reaching the intensity of a 
psychiatric disorder.
 – The clinical experience with CF patients is richer than what can be grasped by studies 
which are solely based on psychometric measurements.
 – Longitudinal and qualitative studies may sometimes be better tools to understand de-
velopmental processes and to address underlying psychic dynamics and evolution of 
the patients and their families.
 – Some other psychological issues which may be observed in CF patients are listed in 
Table 3. 
Table 3: Psychological issues which may be observed in CF patients 
– Disordered eating 
– Low self-esteem
– Social dependency
– Social withdrawal
– Feelings of guilt
– Anhedonia
–  Disturbed intimacy (e.g. strong desire for intimate relationships, which are at the same time 
out of reach because of an avoidant behavior due to fears) and/or disturbed sexuality
– Discrepancy between intellectual abilities and a certain emotional immaturity
– Conflicts or ambivalence regarding autonomy issues
– Development of secondary alexithymia*a under prolonged, heavy treatment and suffering
– Disturbed family functioning with over – and/or underprotection*b
–  Traumatic experience of the disease (sometimes related to more specific symptoms such as 
needle related phobia)
*a Difficulty in recognizing or expressing personal emotions
*b Within the family, anxiety, repressed aggression and guilt may lead to overprotection and separation/autonomy difficulties
4. ASSESSMENT AND MANAGEMENT 
4.1 For CF patients
jj Screening: An annual screening by a trained psychologist or psychiatrist should be of-
fered to CF patients in order to evaluate their psychological difficulties and possible psy-
chiatric symptomatology. A face-to-face interview is advisable and can be complemented 
by questionnaires. 
js This annual screening may improve patient understanding and care and is a first step 
to ease a potential crisis-related subsequent consultation. The main objectives of the 
annual screening interview with the CF psychologist or psychiatrist are presented in 
Table 4.
js Although the use of questionnaires is less preferable than a face-to-face inter-
view held by a trained psychologist or psychiatrist, in settings where no psychologist 
works within the team, the use of questionnaires (Table 5) can help identify psycholo-
gical problems for which referral to a mental health worker may be indicated. 
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js Patients with psychiatric symptoms should be offered appropriate psychological 
treatment and follow-up. If necessary, medication should be introduced by a psychia-
trist (see section 5).
jj Interventions during life events: In addition to the annual screening, whenever the phy-
sician perceives psychological vulnerability in a CF patient, psychological support should 
be proposed. As previously mentioned, psychological vulnerability may be more evident 
during life events (Figure 1, Table 2).
jj Transition from pediatric to adult care: the psychologist should be integrated as soon 
as possible in the process especially in complex situations. A common meeting with the 
child’s psychiatrist/psychologist in the pediatric ward or at least a first meeting soon after 
transition is recommended. 
jj Parenthood (see also Chapter “Fertility and pregnancy”): 
js The majority of male CF patients (95%) are infertile. Information about infertility has often 
a strong psychological impact; if assisted reproduction is too expensive, patients may 
have to renounce biological fatherhood.
js For females, increased attention for psychological vulnerability is crucial during  the 
antenatal and postnatal periods; complications during pregnancy may lead to psycho-
logical suffering and adjustment difficulties with the newborn. 
js Fear of a premature death, before the child has grown up, is common. 
jj Transition to transplantation (see also Chapter “Transplantation”): 
js A psychiatric assessment by an expert is part of the pre-transplantation evaluation, in 
order to assess the patient’s psychiatric suitability for transplantation. 
js Psychological support may be necessary and should be systematically offered in this 
context, since every step in the transplantation process is associated with psychological 
challenges (Table 6).
js Transition to palliative care: psychological support should be offered for the  patients, 
but also family and friends, before and after the patient dies (see also Chapter, 
“Palliative and end-of-life care”).
Table 4:  Main objectives of  the annual screening interview with the CF  
psychologist or psychiatrist
It helps explore and assess :
– Mental health
– Quality of life
– Potential risk factors for psychological vulnerability 
– Resources of the patient
– His/her representations of illness and treatment
–  Experiences regarding treatment (including adherence problems, relationship with health 
care professionals)
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Table 5: Questionnaires used in CF  
Target Questionnaire Available at  / Reference
Anxiety/
Depression
PHQ-2 / PHQ-9*1,2 www.phqscreeners.com/
GAD-2 /GAD-7*1,2 www.phqscreeners.com/
HADS*1, 2 http://opencourses.emu.edu.tr/pluginfile.
php/8619/mod_resource/content/1/HADS.pdf
HDRS*1,2 http://dcf.psychiatry.ufl.edu/files/2011/05/
HAMILTON-DEPRESSION.pdf
Quality of Life CFQoL In: (Gee L. , Abbott, Conway, Etherington, & 
Webb, 2000)
CFQ-R*1,2 www.psy.miami.edu/cfq_QLab/
Adherence MMAS*1,2 In: (Morisky, Ang, Krousel-Wood & Ward, 2008)
Eating attitudes 
and Behaviors
CFEAB In : (Randlesome, Bryon, & Evangeli, 2013)
Eating Issues & Body 
Image continuum
www.health.arizona.edu/sites/health/files/
continuum2.pdf
Self-esteem Rosenberg Self-esteem 
Scale*1,2
www.yorku.ca/rokada/psyctest/rosenbrg.pdf
*1 Available in French
*2 Available in German
Table 6: Psychological challenges during the transplantation process
Time point Examples of psychological challenges
Referral for transplantation Understanding the acuteness of illness and coping with the 
possibility of death
Waiting period Fear of dying before an organ is available
Guilt of wishing someone to die in order to receive an organ
Post-transplant phase Integration of someone else’s organ
Facing a future which was not expected
Disillusions regarding a completely symptom-free life
4.2. For parents and siblings
jj Research indicates that parents of children and teenagers with CF show elevated rates 
of anxiety and depression. This probably applies to parents of adult patients and si-
blings as well. Therefore, special attention should be paid to the parents and siblings. If 
necessary, the psychologist should be able to refer them for appropriate mental health 
care.
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4.3. For the CF team
jj The importance of an integrated disease management approach for CF patients is now 
well established. In line with this concept, CF teams should include a trained psycho-
logist/psychiatrist, offering direct consultations for the patients as well as advice 
to the other team members regarding the psychological understanding of patients 
(consultation and liaison activity). 
jj Considering the psychological impact of working with CF patients, especially in pre-
transplant periods or palliative care, team supervision by a psychologist/psychiatrist 
should be offered. 
jj Issues such as potential negative feelings or conflicts with patients are also part of what 
can be formally or informally discussed with a psychologist.
jj The mental health care worker can provide advice regarding important issues such as 
adherence. Table 6 presents examples of coping strategies that may be offered to the CF 
team in regard to adherence problems.
Table 6:  Examples of coping strategies for adherence issues (for physicians and 
CF nurses)
Prevention and management:
– Address the issue of adherence early, if necessary as soon as the transition begins.
–  Talk about it in an open and non-judgmental way, without taboo. Make sure the patient 
understands the treatment. Avoid using medical jargon.
–  Explore reasons for non-adherence with respectful curiosity, and not on the premise that 
it is due to some defective reasoning of the patient (such as irrational fears or lack of 
understanding of the severity of the disease)
–  Explain that this is a common issue, and that some degree of forgetting or nonadherence 
is normal.
– Explore patient perception of his/her treatment (is it useful or not?).
–  Always be open about the consequences of non-adherence but better make compro-
mises than lose the communication with the patient.
–  Set realistic goals. Try to establish an oral contract/agreement the patient feels comfor-
table with. If necessary, put it on paper in order to make it clear for both patient and 
health professionals.
– Try to empower the patient and help him/her face his/her responsibilities.
– Address the issue of alternative treatments  often used by patients.
Work in collaboration with:
–  The caregivers, to explore whether the patient can benefit from a supportive group such 
as family or friends.
–  The mental health worker, in order to detect psychological suffering or mental health 
issues related to non-compliance. The psychologist can also provide the patient with 
specific tools or therapy (e.g. motivational interviewing).
–  The social worker, in order to explore the social or financial issues possibly related to 
non-adherence.
–  The physiotherapist, to set treatment goals.
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Table 7: Psychiatric drugs and specific considerations in CF – not an exhaustive list 
Classes Pharmacological considerations CF-related considerations
Antidepressants*a
1st choice Selective serotonin 
reuptake inhibitors 
(SSRI)
–  Drug interactions through inhibition of 
liver P450 enzymes*b 
–  Relative contraindication to use with 
linezolid
– QT prolongation*c
–  Reported associations with bleeding 
risk, bone fractures (observational 
studies)
– Weight gain
Citalopram:  lower probability of drug interactions compared to other SSRI, dose- 
dependent QT interval prolongation
Escitalopram: lower probability of drug interactions compared to other SSRI
Fluoxetine: long half-life, strong inhibitor of CYP 2D6
Paroxetine: mild anticholinergic side effects
Sertraline: diarrhea more frequent compared to other SSRI
2nd choice Serotonin-
norepinephrine 
reuptake inhibitors 
(SNRI)
–  Administering with food may reduce nau-
sea without influencing absorption
–  Anticholinergic side effects (indirect 
decrease of the parasympathetic tone)
–  Reported associations with bleeding 
risk, bone fractures  (observational 
studies)
Duloxetine: inhibitor of CYP2D6*a
Venlafaxine: QT prolongation*b, possible increase in diastolic blood pressure and/or 
heart rate
3rd choice Tricyclic and tetracy-
clic antidepressants
–  Sedative properties (blockage of hista-
mine receptors).
–  Lethal potential of overdosing (SSRI, 
SNRI are considered safer in this regard)
–  Drug interactions as substrates of P450 
enzymes*b 
–  Anticholinergic symptoms (higher rates 
compared to SSRI, SNRI) 
–  Cardiovascular screening before treat-
ment initiation
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Monamine oxidase 
inhibitors
Not considered first-line antidepressants 
(need of dietary restrictions, many drug 
interactions and side-effects)
–  Not considered first-line antidepres-
sants (need of dietary restrictions, many 
drug interactions and side-effects)
–  Anticholinergic symptoms
Other 
antidepressants
Mirtazapine, trazodone: to be considered  
in case of sleep disorders
– Anticholinergic symptoms (usually mild)
Anxiolytics Benzodiazepines –  Inhibitors of the CYP3A4 system increase 
the risk of benzodiazepine toxicity whe-
reas inducers of the CYP3A4 system may 
decrease their effectiveness*a
Avoid use in patients with respiratory 
insufficiency
Lorazepam: fewer P450 interactions compared to other benzodiazepines
Oxazepam: fewer P450 interactions compared to other benzodiazepines
Antipsychotics Extrapyramidal side effects, QT 
prolongation*b 
Potential weight gain and development  
of a metabolic syndrome
Anticholinergic symptoms
CNS stimulants Dry mouth, decreased appetite and 
weight loss
Cardiovascular side effects
*a SSRI, SNRI and tricyclics have also demonstrated their efficacy for anxiety disorders. SSRIs (especially sertraline and escitalopram) are the first-line agents for the 
long term treatment of anxiety disorders whereas benzodiazepines are used mostly to manage acute symptoms. There is a delay of 1-6 weeks for the effect of SSRIs 
on depression and 4-8 weeks for the effect on anxiety disorders.
*b Details on inhibitors, inducers and substrates of P450 enzymes can be found in  http://medicine.iupui.edu/clinpharm/ddis/main-table and http://bioinformatics.
charite.de/supercyp/index.php?site=home. 
*c Examples of QT prolonging agents: azole antifungals, macrolides, quinolones 
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5. PHARMACOTHERAPY
jj Introduction of an antidepressant drug should be discussed with the CF team and the 
psychologist/psychiatrist.
jj Most adverse effects are dose dependent, some are transient [e.g. nausea and headaches 
for Specific Serotonin Reuptake Inhibitors (SSRI)] and others persistent (e.g. anticholinergic 
effects).
jj Therapeutic drug monitoring (TDM) is recommended in case of potential interactions, sus-
pected genetic metabolism anomaly or to document adherence.
jj Secondary effects relevant to CF:
js Many molecules are associated with anticholinergic symptoms (e.g. constipation, dry 
secretions) at various degrees, and these may be particularly problematic in CF patients.
js The associations of SSRI (and Serotonin-Norepinephrin Reuptake Inhibitors – SNRI) 
with bleeding risk (notably gastrointestinal bleeding) and bone fractures are based on 
observational studies and are not unequivocally established.
jj CF patients often receive multiple medications: 
js Drug interactions with psychiatric drugs usually concern inhibition or induction of liver 
P450 metabolism or potentiation of common secondary effects (e.g. QT prolongation). 
js Of note, the relative contraindication to administer linezolid in patients receiving SSRI 
due to the risk of serotonin syndrome.
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